Home › Companies › NRXP

NRX Pharmaceuticals

Market cap $109M 44.3M shares (10-Q, Nov 16, 2026) × $2.45 close Nov 17, 2026

Most recent annual filing: 2026-03-23

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. NRX-101 Ph3 start2026NRX-101 Ph3 start, 2026, routine
  2. SPARC-TMS TMS trial start4Q 2026SPARC-TMS TMS trial start, 4Q 2026, routine
  3. DARPA contract corporate update4Q 2026DARPA contract corporate update, 4Q 2026, routine
  4. Corporate financials filingNov 2026Corporate financials filing, Nov 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (11 active programs)

Technology platforms

NMDA platform

NMDA receptor-targeting platform for central nervous system disorders including suicidal depression, chronic pain, and PTSD

Targets: NMDA

NMDA receptor platform

NMDA receptor-targeting drug development platform focused on central nervous system disorders including suicidal depression, chronic pain, and PTSD

Targets: NMDA receptor

Capital (as filed)

Cash
$19.8M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$6.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$19.8M cash per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (18)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (18 calls)

Every verdict Biotech Distilled has published on NRX Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch NRx Pharmaceuticals (NRXP): Scientific Deep Dive for KETAFREE™ Science is plausible but balance sheet is terrifying; wait for FDA signal on preservative ban before committing capital.
  2. Watch UPDATE: NRx Pharmaceuticals (NRXP) — The Proxy Drops (And the Math is Ugly) Proxy confirms massive dilution is being modeled into executive compensation; corporate finance reality is toxic despite plausible science.
  3. Watch UPDATE: NRX Pharmaceuticals (NRXP) - The FDA Blinks... FDA de-risked the NRX-100 pathway materially but a likely secondary offering ahead of earnings keeps the stock on the sidelines.
  4. Watch UPDATE: NRX Pharmaceuticals - The 10-K Drops, The ATM Spins, and the Evergreen Grab Passes 10-K confirms 100%+ dilution in 2025 and active ATM; dilution gap thesis validated, retail investors are just footing the bill for clinical trials.
  5. Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - The Hail Mary Becomes a Layup Three cleared FDA review disciplines and a Presidential EO have materially de-risked the regulatory thesis; wait for the inevitable capital raise to price before entering.
  6. Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - The Fertilizer Trial Gets a Green Light MIND1 IND clearance validates the NRX-101 fertilizer-effect thesis but is a 2027-2028 catalyst; entry still gated on the inevitable capital raise.
  7. Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - The ATM Receipts Arrive (And a Swiss Surprise) NRX-100 thesis intact and tracking toward Summer 2026 approval; ATM drip already happened at $2.00-$2.94 rather than a discrete offering, complicating the entry-point setup.
  8. Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - The Underwritten Raise Finally Prints The underwritten secondary has finally materialized; wait for the offering to price and look for entry below the offering price with a defined exit at the Summer GDUFA decision.
  9. Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - The Print Lands at $3.50 Offering priced at $3.50 (24% discount); dilution gap bridged through GDUFA decision; consider entering near the offering price with a defined exit at the Summer GDUFA decision.
  10. Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - Kadima Sues, Zeta Goes Live Kadima litigation narrows HOPE footprint but doesn't move the NRX-100 GDUFA binary; post-deal soft patch still forming near the $3.50 print.
  11. Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - DARPA Picks Up the Phone DARPA selected SPARC-TMS for negotiation, providing a plausible non-dilutive funder for NRX-101; near-term binary remains the Summer GDUFA decision on NRX-100.
  12. Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - The Cap, Not the Compound FDA cleared the drug on every substantive discipline and flagged only a plastic cap attestation; timeline slipped but thesis intact, funded by the June raise.
  13. Hold UPDATE: NRx Pharmaceuticals (NRXP) - The ATM Never Went Dormant Burn rate re-based to $2.2M/month, ATM ran through the quarter described as dormant, and share count up 36% YTD; dilution gap was refinanced not closed, warranting a downgrade to HOLD.
  14. Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - Major Becomes Minor, and the Clock Gets a Date FDA reclassified the vial-cap amendment from Major to Minor and set a hard GDUFA goal date of November 10, converting an open-ended cash drain into a defined eight-week hold with a dated outcome.
  15. Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - The Contract Number Arrives DARPA awarded an $11.2M prime contract for SPARC-TMS, meeting the bar set in May; trade still turns on the November 10 GDUFA date for NRX-100.
  16. Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - The Envelope Passed. The Tape Didn't Care. FDA approved preservative-free ketamine ANDA ahead of the November 10 goal date; regulatory risk is gone but the trade is now a launch-and-dilution bet on a generic with no disclosed pricing or exclusivity.
  17. Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - The Envelope Becomes the Moat 17-person sales force launched but shipments start January 2027, the same quarter management's cash runway ends; hold through first shipments pending signed supply contracts.
  18. Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - Q3 Status Check: The ATM Napped, the NDA Slipped Zero Q3 ATM sales and $19.8M cash matched the model, but the branded NDA slipped at least two quarters on a PHQ-9/MADRS comparability question and a $712K aircraft purchase signals governance concerns.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (48)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

1 more filing (13G holder notices, S-8, proxy material, SEC correspondence …)